Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates
Globe Newswire•16/11/2026•16:14 ET
0
Key Highlights
- ➤Olvi-Vec Phase 3 OnPrime ovarian cancer topline data expected in 2H26
- ➤Pro forma cash and investments reached $15.5 million after $5.1 million ATM proceeds
- ➤Q3 R&D expenses rose to $6.9 million as Phase 3 trial costs increased
- ➤Q3 net loss widened to $10.3 million, or $0.23 per share
- ➤SCLC patient achieved 84.6% tumor reduction, 16.7-month PFS and 14.3-month response duration
Expert Statements
Thomas Zindrick, President, CEO and Chairman of Genelux
“We continue to make meaningful progress across our clinical programs as we advance toward anticipated Phase 3 OnPrime topline data and additional lung cancer updates”
Thomas Zindrick, President, CEO and Chairman of Genelux
“We were also encouraged by the recent publication of a deep and durable response in a platinum-relapsed small cell lung cancer patient following systemic Olvi-Vec administration, which further supports the potential of our systemic approach and the opportunity to broaden the clinical utility of the program across lung cancer treatment settings.”
Thomas Zindrick, President, CEO and Chairman of Genelux
“At the same time, we have continued to advance the manufacturing, operational and commercial capabilities needed to support the next phase of growth.”
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --
-- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer --
Get started
Create a free account to read the full story.
